DarioHealth Corp.Find Ratings Reports
DARIOHEALTH CORP's gross profit margin for the second quarter of its fiscal year 2019 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased. DARIOHEALTH CORP has average liquidity. Currently, the Quick Ratio is 1.48 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 46.66% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY19||Q2 FY18|
|Net Sales ($mil)||1.65||2.06|
|Net Income ($mil)||-5.38||-5.84|
|Balance Sheet||Q2 FY19||Q2 FY18|
|Cash & Equiv. ($mil)||8.17||5.19|
|Total Assets ($mil)||12.33||8.1|
|Total Debt ($mil)||0.79||0.0|
|Profitability||Q2 FY19||Q2 FY18|
|Gross Profit Margin||27.56||27.68|
|Return on Assets||-160.66||-185.2|
|Return on Equity||-324.97||-379.01|
|Debt||Q2 FY19||Q2 FY18|
|Share Data||Q2 FY19||Q2 FY18|
|Shares outstanding (mil)||42.86||21.08|
|Div / share||0.0||0.0|
|Book value / share||0.14||0.2|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||94176.0||118806.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.04 indicates a discount versus the S&P 500 average of 3.24 and a significant discount versus the subsector average of 8.54. The price-to-sales ratio is below the S&P 500 average and is well below the subsector average, indicating a discount. After reviewing these and other key valuation criteria, DARIOHEALTH CORP proves to trade at a discount to investment alternatives.
|DRIO NM||Peers 52.11||DRIO NM||Peers 36.32|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
DRIO's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
DRIO's P/CF is negative making the measure meaningless.
|DRIO NM||Peers 35.34||DRIO NA||Peers 1.14|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
DRIO's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|DRIO 2.04||Peers 8.54||DRIO 47.33||Peers 47.49|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
DRIO is trading at a significant discount to its peers.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
DRIO is expected to keep pace with its peers on the basis of earnings growth.
|DRIO 1.66||Peers 6.20||DRIO 10.40||Peers 8.37|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
DRIO is trading at a significant discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
DRIO has a sales growth rate that exceeds its peers.